Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Vectura Group Plc (VEGPF)

Vectura Group Plc (VEGPF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 487,304
  • Shares Outstanding, K 612,961
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 03/26/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7950 unch
on 03/18/20
1.1200 -29.02%
on 02/27/20
-0.2631 (-24.87%)
since 12/02/19
3-Month
0.7950 unch
on 03/18/20
1.1200 -29.02%
on 02/27/20
-0.2950 (-27.06%)
since 11/01/19
52-Week
0.7950 unch
on 03/18/20
1.1200 -29.02%
on 02/27/20
-0.2267 (-22.19%)
since 03/15/19

Most Recent Stories

More News
Nasal Drug Delivery Devices Market to Reach USD 81.85 Billion by 2026, Market to Gain from Increasing Patient Population, Predicts Fortune Business Insights(TM)

The global Nasal Drug Delivery Devices Market size is prognosticated to reach USD 81.85 billion by 2026 attributable to the increasing number of the patient population and the rising prevalence of pulmonary...

ATR : 94.00 (-2.29%)
TEVA : 7.56 (-4.30%)
VEGPF : 0.7950 (-29.02%)
Actinic (Solar) Keratosis Treatment Market Analysis with Lucrative Strategies and Irreplaceable Counsel by 2025

The Big Market Research has recently added a new survey report to their vivid and dynamic database. They have formulated this report by taking into consideration all the key aspects that tend to have an...

ATNX : 7.53 (-12.95%)
FOMX : 2.99 (-7.72%)
VRX.TO : 30.80 (-3.33%)
VEGPF : 0.7950 (-29.02%)
Avacta Group plc Appoints Paul Fry as Non-Executive Director

Avacta Group plc (AIM: AVCT), the developer of Affimer(R) biotherapeutics and reagents, is pleased to announce the appointment of Paul Fry as Non-Executive Director with effect from 3 February 2020.

VEGPF : 0.7950 (-29.02%)
Actinic (Solar) Keratosis Treatment Market Development Study: Big changes will have a big Impact

HTF MI recently introduced latest version Actinic (Solar) Keratosis Treatment Market Study 2019. It covered product Scope, Market Share, Size, Revenue, Opportunities, Growth Rate, Sales Growth, Demand,...

FOMX : 2.99 (-7.72%)
VRX.TO : 30.80 (-3.33%)
VEGPF : 0.7950 (-29.02%)
Actinic (Solar) Keratosis Treatment Market to witness major growth in coming years

Ameco Research Presents “” New Document to its Studies Database. The Report Contain 116 Pages With Detailed Analysis.

ATNX : 7.53 (-12.95%)
FOMX : 2.99 (-7.72%)
NVS : 79.28 (-0.58%)
VRX.TO : 30.80 (-3.33%)
VEGPF : 0.7950 (-29.02%)
Global Actinic (Solar) Keratosis Treatment Market : Global Market Analysis By Segment, Region, Growth & Forecast 2019-2025

The market size of Actinic (Solar) Keratosis Treatment is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$...

ATNX : 7.53 (-12.95%)
FOMX : 2.99 (-7.72%)
NVS : 79.28 (-0.58%)
VRX.TO : 30.80 (-3.33%)
VEGPF : 0.7950 (-29.02%)
Vectura Wins US GSK Patent Litigation and Awarded $89.7Million in Damages by Trial Jury

Vectura Group plc (LSE:VEC) ("Vectura" or "the Group")confirmsthaton 3rd May 2019following a jury trial in the United States District Court for the District of Delaware, the relevant asserted...

GSK : 36.44 (-2.17%)
VEGPF : 0.7950 (-29.02%)
VEC : 39.79 (-1.95%)
Global (United States, European Union and China) Actinic (Solar) Keratosis Treatment Market Research Report 2019-2025

In 2019, the market size of Actinic (Solar) Keratosis Treatment is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million...

FOMX : 2.99 (-7.72%)
NVS : 79.28 (-0.58%)
VRX.TO : 30.80 (-3.33%)
VEGPF : 0.7950 (-29.02%)
Trade VEGPF with:

Key Turning Points

2nd Resistance Point 0.7950
1st Resistance Point 0.7950
Last Price 0.7950
1st Support Level 0.7950
2nd Support Level 0.7950

See More

52-Week High 1.1200
Fibonacci 61.8% 0.9958
Fibonacci 50% 0.9575
Fibonacci 38.2% 0.9191
Last Price 0.7950
52-Week Low 0.7950

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar